The Federal Government Will Spend Up to $4.9 Million to Prepare Ibogaine Trials for Veterans With PTSD
Health Secretary Robert F. Kennedy Jr. and Veterans Affairs Secretary Doug Collins announced up to $4.9 million over five years on Nov. 12 to lay the groundwork for the first U.S. studies of ibogaine for veterans with PTSD. The money pays for manufacturing, dosing and study design, not for treating patients yet. Beond, a Texas-based company that says it has treated more than 3,000 people with ibogaine at its clinic in Mexico, will share data and treatment guidance. "For veterans living with PTSD, we owe them both urgency and the best science we can produce," Collins said. Kennedy said officials may also fund work on ibogaine for addiction. The same day, the National Institute of Mental Health posted a $20 million funding notice for a research network on fast-acting drugs such as ketamine, esketamine and psilocybin, with awards expected in summer 2027.
Why it's slow: ibogaine is still Schedule I and can cause dangerous irregular heart rhythms, so clinics monitor patients' hearts with emergency help on standby. Treatment in Mexico typically costs $10,000 to $20,000. The announcement follows President Trump's April executive order on psychedelic research, and comes days after the DEA proposed 57 times more ibogaine for research in 2027. Rep. Morgan Luttrell (R-TX), a retired Navy SEAL, is one of the lawmakers on record about his own ibogaine treatment in our People Series: Politicians. Reported by the AP's Matthew Perrone and Military.com's Katherine Plummer.